CN103083404A - Nasal cavity protective agent - Google Patents
Nasal cavity protective agent Download PDFInfo
- Publication number
- CN103083404A CN103083404A CN 201310012097 CN201310012097A CN103083404A CN 103083404 A CN103083404 A CN 103083404A CN 201310012097 CN201310012097 CN 201310012097 CN 201310012097 A CN201310012097 A CN 201310012097A CN 103083404 A CN103083404 A CN 103083404A
- Authority
- CN
- China
- Prior art keywords
- nasal cavity
- protective agent
- oil
- percent
- mucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an external nasal cavity protective agent used for allergic rhinitis, acute rhinitis and other nasal cavity and respiratory mucosa inflammations. The using method of the protective agent comprises the step of daubing the protective agent on the front section of the nasal cavity. The nasal cavity protective agent comprises the following components in percentage by weight: 2-30 percent of eucalyptus oil, 2-30 percent of tea tree oil, 2-30 percent of peppermint oil, 2-30 percent of lavender oil, 1-2 percent of enteromorpha oil and 40-90 percent of edible plant oil. The external nasal cavity protective agent has the functions that 1, the protective agent has the antihistamine function, has high effect on allergic rhinitis, acute rhinitis and the like and is fast in effect and durable in effect; 2, the nasal cavity and respiratory mucosa can be activated, and the capacity of the respiratory mucosa for resisting microbial infection is improved; 3, the nasal cavity biological environment is improved, the other symptoms of the nasal cavity are relieved, and the mucosa wound healing is promoted; 4, the protective agent has the functions of inhibiting bacteria, moulds, mycoplasma, viruses and other microbes; 5, the protective agent has the protective functions of delaying water evaporation and isolating sensitizing and pathogenic factors on the nasal cavity mucosa; 6, the protective agent is highly safe to human mucosa tissue and has a health-care function; and 7, the protective agent is convenient to use and high in economical efficiency.
Description
Technical field
The present invention relates to a kind of nasal cavity protective agent for human body nasal cavity inflammation (being specially adapted to allergic rhinitis).
Background technology
Nasal cavity is the primary barrier of upper respiratory tract health.Pathological changes very easily occurs because various external environment condition reasons and human body self pathology stimulate in bronchia mucosal.Various nasal cavity inflammations, particularly allergic rhinitis is the most easily to occur and modal nose diseases, not only directly cause suffering to the patient, and nearly allergic rhinitis more than 40% can be converted into allergic asthma etc., health is caused larger harm.At present, because the mechanism of the allergic respiratories such as allergic rhinitis is difficult to explain, it is so difficult medical problem that treatment and prevention are appointed.
The present invention is comprised of the plant component of integration of edible and medicinal herbs, and human body is had affinity preferably.Wherein eucalyptus globolus oil and tea tree oil have the effect of anti-mucositis, play Germany, the French oral drugs of just using it for respiratory system in 1854.Oleum lavandula angustifolia can promote wound healing, and patient is had sedation.Oleum menthae can volatilize fast, promotes drug effect.The inorganic salt such as the contained sodium alginate of Entermorpha oil, plant collagen, iodine and the not bright factor are conducive to the growth of mucosa cells, are also the constituent of respiratory tract mucus.
Prescription of the present invention has clear and definite protective effect to nasal cavity and upper respiratory tract, particularly has significant anti-allergic effects.1, improve the vigor of bronchia mucosal, increase the quality and quantity of mucus, comprise rare cunning, the mobility (being different from clear water sample watery nasal discharge) of antimicrobial component content such as improving mucopolysaccharide, mucin, lysozyme in mucus and mucus, make nasal cavity form rational physiological environment; 2, promote ciliary movement, improve amplitude of fluctuation and frequency, accelerate purulent secretion and discharge, promote that inflammation disappears; 3, form pharmaceutical film on bronchia mucosal surface, isolation harmful gas and dust make to breathe to produce joyful sense, and reach the effect of the upper respiratory disease such as Polyglucan rhinitis.
Summary of the invention
The invention provides a kind of via intranasal application leading portion smears administration, the human nasal cavity protective agent that resists multiple extremely quick factor effect, improves physiology of the nose environment, elimination nasal cavity and upper respiratory tract infection is arranged.The protectant constituent of nasal cavity of the present invention and percentage by weight are: eucalyptus globolus oil 3 ~ 30%, tea tree oil 3 ~ 30%, Oleum menthae 3 ~ 20%, Oleum lavandula angustifolia 3 ~ 30%, Entermorpha oil 1 ~ 5%, all the other are edible vegetable oil.
Nasal cavity protective agent of the present invention makes its Terpinen-4-ol: 3 ~ 30%, terpinene: 2 ~ 20% by the addition of controlling composition composition.The described various compositions of this nasal cavity protective agent; has different separately effects; make the wherein collaborative synergistic effect of effective ingredient generation through reasonable formula, make this nasal cavity protective agent have the effect of obvious antianaphylaxis inflammation, inhibition growth of microorganism, the mucus secretion of promotion nasal cavity and mucosa wound healing.Its concrete function shows:
1, the distinctive volatility of plants essential oil, make ingredient discharge fast, and absorption of human body speed is accelerated, and eliminates fast the abnormal stress of nasal cavity;
2, impel the macrophage response ability to strengthen, in mucus, the content of mucopolysaccharide, mucin and lysozyme improves, and improves the anti-infection ability of mucosa;
3, promote the slipping of mucus secretion and raising mucus, be beneficial to the inflammation secretions discharges such as nasal mucus, reduce moisture under mucosa, eliminate the bronchia mucosal congestion and edema, improve the mucositis symptom;
4, form at mucous membrane surface the gelatinous layer that Vegetable oil lipoprotein and sodium alginate etc. form, play the protective effect that reduces the moisture evaporation, isolates the sensitizing factor that causes a disease.
Advantage applies of the present invention exists:
1, quick-acting.Be applied in the nasal cavity leading portion after 2 ~ 5 minutes when morbidity, just can alleviate the nasal cavity mucositis, as symptoms such as watery nasal discharge, sneeze, nasal obstruction, dryness in the nasal cavity, burn feelings;
2, efficient.Clearly effective to nasal cavity inflammations such as rhinitis, flu, sinusitis, especially the allergic rhinitis obvious effective rate is reached more than 90%, cure rate is more than 60%.Child and the treatment of teen-age allergic rhinitis generally are no more than 10 days, and cure rate may be relevant by force with its body growth recovery capability near 100%();
3, long-acting.The medication interval time is long, smears 1 ~ 3 every day and gets final product.After the symptom recovery from illness, stabilization time is long;
4, wide spectrum.Effective to various respiratory road symptoms (even snoring) such as rhinitis.Most anaphylactogens are had desensitization, and the treatment allergic conditions needn't be distinguished anaphylactogen;
5, safety.Adopt natural component, overall process adopts physical method to manufacture.Do not contain chemical combination composition, antibiotic, ephedrine, hormone, (oral test, 500 times approximately 50 milliliters of using an applying amount of nasal cavity, the disposable oral untoward reaction that has no) has no side effect;
6, economy.Compare surgical operation and other oral drugs, nasal cavity protective agent economy of the present invention is remarkable;
7, convenient.The nasal cavity protective agent can use the bottle packing, is easy to carry, and old children all can smear voluntarily, and is easy and simple to handle;
8, health care.Be conducive to improve the oxygen exchange level of human body, and then the motor capacity that may improve human body.
The specific embodiment
The eucalyptus globolus oil that nasal cavity protective agent of the present invention adopts, tea tree oil, Oleum menthae, Oleum lavandula angustifolia are distilled gained by stem and leaf and the flower of described plant, and Entermorpha oil is by sea-plant Entermorpha and edible vegetable oil squeezing gained.By controlling various composition additions in engagement process, make it contain Terpinen-4-ol: 3 ~ 30%; Terpinene: 2 ~ 20%.
Above-described embodiment uses checking through the experimenter, comprises that for various nose diseasess the discomfort that anaphylactic disease produces has clear and definite mitigation, has protective effect to bronchia mucosal.
Claims (3)
1. nasal cavity protective agent is characterized in that: its constituent and percentage by weight be, eucalyptus globolus oil 3 ~ 30%, and tea tree oil 3 ~ 30%, Oleum menthae 3 ~ 20%, Oleum lavandula angustifolia 3 ~ 30%, Entermorpha oil 1 ~ 5%, all the other are edible vegetable oil.
2. nasal cavity protective agent according to claim 1, is characterized in that: contain Terpinen-4-ol: 3 ~ 30%; Terpinene: 2 ~ 20%.
3. according to claim 1,2 described nasal cavity protective agents, its occupation mode is: before the nostril of nasal cavity leading portion and the smearing of 1 ~ 2cm place, inboard, nostril.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310012097 CN103083404A (en) | 2013-01-14 | 2013-01-14 | Nasal cavity protective agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310012097 CN103083404A (en) | 2013-01-14 | 2013-01-14 | Nasal cavity protective agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103083404A true CN103083404A (en) | 2013-05-08 |
Family
ID=48196883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310012097 Pending CN103083404A (en) | 2013-01-14 | 2013-01-14 | Nasal cavity protective agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103083404A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877601A (en) * | 2014-03-25 | 2014-06-25 | 湖北科田植萃精华有限公司 | Extracted plant essence ventilation tablet and preparation method thereof |
| CN104547044A (en) * | 2014-12-22 | 2015-04-29 | 章迅 | Medicinal composition for preventing and treating upper respiratory inflammation and preparation and application thereof |
| CN108126129A (en) * | 2018-02-10 | 2018-06-08 | 鄂尔多斯市蔚蓝生物科技有限公司 | A kind of nasil preparation for being used to treat rhinitis |
-
2013
- 2013-01-14 CN CN 201310012097 patent/CN103083404A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877601A (en) * | 2014-03-25 | 2014-06-25 | 湖北科田植萃精华有限公司 | Extracted plant essence ventilation tablet and preparation method thereof |
| CN104547044A (en) * | 2014-12-22 | 2015-04-29 | 章迅 | Medicinal composition for preventing and treating upper respiratory inflammation and preparation and application thereof |
| CN108126129A (en) * | 2018-02-10 | 2018-06-08 | 鄂尔多斯市蔚蓝生物科技有限公司 | A kind of nasil preparation for being used to treat rhinitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2949139T3 (en) | Composition that eliminates nasal congestion and has antiviral activity | |
| CN113332244B (en) | Antiviral oral spray and preparation method thereof | |
| ITRM20130716A1 (en) | COMPOSITION FOR USE IN THE TREATMENT OF PERSISTENT COUGH | |
| CN103083404A (en) | Nasal cavity protective agent | |
| CN103223015A (en) | Muscle soreness and skin itch treatment drug composition and preparation method thereof | |
| WO2003018042A1 (en) | Compositions for treatment and prevention of cold having antiviral activity | |
| US20060210482A1 (en) | Chemical composition and method for cold and sinus relief | |
| CN105250385A (en) | Nasal drops for treating infant nasal obstruction | |
| CN111012823A (en) | Medicine containing lindera glauca volatile oil and administration method thereof | |
| US20210077422A1 (en) | Cannabinoid formulation including synergistic organosulphur compounds | |
| JP2012193159A (en) | Nasal spray | |
| CN113785847A (en) | A fumigant with effects of eliminating dampness, removing toxic substance and avoiding plague, and its preparation method | |
| CN1276765C (en) | Incense fumigating agent for coryza | |
| CN111388571A (en) | Compound essential oil for treating rhinitis and cold | |
| CN112602732A (en) | Epidemic prevention traditional Chinese medicine essential oil formula | |
| CN104547128A (en) | Medicine for treating rhinitis | |
| CN104524519A (en) | Special handkerchief paper suitable for patient suffering cold in the bud | |
| US20160015630A1 (en) | Sprayable oxygenated saline composition and method for treating nasal congestion, allergy, dryness, eye irritation, throat irritation, wounds, and skin as applied to human tissues | |
| MX2012008419A (en) | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. | |
| CN1277551C (en) | Mint oil preparation for treating obstructive sleep apnea and low ventilation syndrome | |
| CN115337359B (en) | External traditional Chinese medicine composition for treating mite dermatitis and preparation method thereof | |
| CN100387249C (en) | Traditional Chinese medicine formulation for treating ulcer | |
| CN116531461A (en) | Epidemic prevention and sterilization double coptis chinensis composition oral and nasal spray and preparation method thereof | |
| CA2856862A1 (en) | Sprayable oxygenated saline composition and use thereof | |
| CN104586691A (en) | Aromatic essential oil spray and application thereof in preparation of special paper handkerchief |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130508 |